Daily close, T-120 (10/8/24) through T+5. Run-up high $40.88 on 10/8/24, low $32.08 on 1/16/25 (T-120 to T-1). FDA decision 3/25/25. Historical price action, not a forecast.
Positioning before the decision
On Mar 11, 2025, 14 days before the decision date, at-the-money options priced a move of ±5.2% through Mar 28, 2025 (the first listed expiry after the decision; ATM implied volatility 30%). The stock closed +0.0% at the first close across the decision and +0.4% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was Blujepa (Gepotidacin) - (EAGLE 2/3) approved by the FDA?
Yes. The FDA approved the application for Blujepa (Gepotidacin) - (EAGLE 2/3) on March 25, 2025. The primary source is linked on this page.
What was Blujepa (Gepotidacin) - (EAGLE 2/3) under FDA review for?
The application covered Uncomplicated urinary tract infection (uUTI). The FDA approved the application on March 25, 2025.
How did GSK stock react to the FDA decision?
On the decision day GSK moved +0.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.